Babies born by cesarean section do not pass through the birth canal and therefore are not exposed to the mother’s vaginal and intestinal microbiome, which plays a key role in the initial colonization of the newborn’s gut microbiota. As a result, these infants show a different composition of microbiota in the early days of life compared to those born vaginally.
Research shows that babies born by cesarean section have lower levels of beneficial bacteria, such as Bifidobacterium and Bacteroides, as well as a slower development of stable gut microbiota during the first weeks of life (Shaterian et al., Open Medicine, 2021).
Clinical studies further confirm that gut colonization in these infants occurs more slowly and follows a different pattern, which may affect the early development of the digestive and immune systems (Li et al., Frontiers in Microbiology, 2020).
Babytol Neonate is recommended for use in infants born by cesarean section with the aim of normalizing gut microbiota, and continuous use is recommended starting from birth, during the first months of life, until the transition to predominantly non-milk nutrition.
Sources
Shaterian N, Abdi F, Ghavidel N, Abdi F.
Role of cesarean section in the development of neonatal gut microbiota: A systematic review. Open Medicine. 2021;16(1):624–639.
A systematic review confirming reduced colonization with beneficial bacteria in babies born by cesarean section.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8035494/
Li SW, Watanabe K, Hsu YH, et al.
Delayed Establishment of Gut Microbiota in Infants Delivered by Cesarean Section. Frontiers in Microbiology. 2020;11:2099.
A study documenting slower and altered gut microbiota colonization in these infants.
https://pubmed.ncbi.nlm.nih.gov/33013766/
In preterm infants, the development of gut microbiota differs significantly compared to full-term infants, primarily due to the immaturity of the digestive and immune systems, as well as the conditions in which gut colonization begins.
Research shows that the gut microbiota in preterm infants is often depleted of beneficial bacteria, particularly genera such as Lactobacillus and Bifidobacterium, indicating a microbiota imbalance in the early neonatal period (Henderickx et al., Frontiers in Cellular and Infection Microbiology, 2019).
Additionally, such dysbiosis may be associated with increased intestinal permeability and inflammatory processes, as confirmed by recent review articles highlighting the need for a targeted approach in the nutritional support of preterm infants (Arboleya et al., Frontiers in Microbiology, 2022).
In order to support the normalization of gut microbiota, Babytol Neonate is recommended for use in preterm infants.
Source
Henderickx JGE, Zwittink RD, van Lingen RA, Knol J, Belzer C. The preterm gut microbiota: an inconspicuous challenge in nutritional neonatal care. Frontiers in Cellular and Infection Microbiology. 2019;9:85.
A review documenting that the gut microbiota of preterm infants shows reduced presence or absence of beneficial bacterial strains such as Lactobacillus and Bifidobacterium, characterizing a dysbiotic state in early neonatal life.
https://pubmed.ncbi.nlm.nih.gov/31001489/
Arboleya S, Rios-Covian D, Maillard F, Langella P, Gueimonde M, Martín R. Preterm delivery: microbial dysbiosis, gut inflammation and hyperpermeability. Frontiers in Microbiology. 2022;12:806338.
A review confirming that preterm infants are characteristically depleted of beneficial bacteria, including Bifidobacterium and Lactobacillus, and that this condition requires nutritional and probiotic support in early postnatal life.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8854986/
The use of antibiotics in early life, especially in hospitalized newborns, can significantly affect the composition of gut microbiota. Although antibiotics are necessary for the treatment of bacterial infections, they do not act selectively only on pathogens, but also lead to a reduction of beneficial bacteria in the intestines.
Research shows that antibiotic therapy in the neonatal period leads to a decrease in bacteria such as Bifidobacterium and Lactobacillus, which may result in microbiota imbalance (dysbiosis) and changes in its function (Pärnänen et al., Journal of Antimicrobial Chemotherapy, 2018).
Recovery of gut microbiota after antibiotic use may take several weeks, during which a gradual restoration of microbial balance occurs (Vangay et al., Cell Host & Microbe, 2015).
Clinical studies indicate that the use of probiotics during and after antibiotic therapy may contribute to faster normalization of the composition and function of gut microbiota in infants (Korpela et al., Microbiome, 2018).
Babytol Neonate is recommended for use in newborns, infants, and young children during antibiotic therapy, as well as for at least three weeks after its completion, in order to support the establishment of a balanced gut microbiota.
Source
Vangay P, Ward T, Gerber JS, Knights D. Antibiotics, pediatric dysbiosis, and disease. Cell Host & Microbe. 2015;17(5):553–564. / Pärnänen KMM et al. Antibiotic therapy in neonates and impact on gut microbiota and antibiotic resistance development: a systematic review. Journal of Antimicrobial Chemotherapy. 2018;73(3):569–581. Sistematski pregled koji dokumentuje da primena antibiotika u neonatalnom periodu dovodi do značajnog smanjenja korisnih bakterija, uključujući Bifidobacterium i Lactobacillus, i da se crevna flora može oporaviti u periodu od nekoliko nedelja po prestanku terapije. https://academic.oup.com/jac/article/73/3/569/4652876
Korpela K, Salonen A, Vepsäläinen O, et al. Probiotic supplementation restores normal microbiota composition and function in antibiotic-treated and in caesarean-born infants. Microbiome. 2018;6(1):182. Randomizovana, dvostruko slepa, placebom kontrolisana studija koja potvrđuje da antibiotici dovode do poremećaja korisne crevne flore i da probiotska suplementacija tokom i nakon antibiotske terapije doprinosi normalizaciji crevne mikrobiote kod novorođenčadi. https://pubmed.ncbi.nlm.nih.gov/30326954/
Babytol Neonate are oral drops that can be added to breast milk or infant formula and are intended to support the establishment and maintenance of balanced gut microbiota in newborns and young children.
The formulation contains a combination of six carefully selected probiotic strains from the genera Lactobacillus and Bifidobacterium: Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus reuteri, Bifidobacterium infantis, Bifidobacterium bifidum, and Bifidobacterium breve. These microorganisms are naturally present in the healthy gut microbiota of infants and play an important role in its development and stabilization.
Scientific studies indicate that a combination of different probiotic strains may contribute to more effective gut colonization and the establishment of microbial balance, particularly in children at increased risk of dysbiosis, such as preterm infants, babies born by cesarean section, and infants exposed to antibiotic therapy (Ruggiero et al., Journal of Pediatric and Neonatal Individualized Medicine, 2024).
Thanks to this combination of strains, Babytol Neonate provides targeted probiotic support during periods when the development of gut microbiota is particularly sensitive.
Source
Ruggiero A, et al. Bifidobacteria, Lactobacilli... when, how and why to use them. Journal of Pediatric and Neonatal Individualized Medicine. 2024. A review documenting that the combination of strains Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, and Lactobacillus rhamnosus GG represents optimal probiotic support for the normalization of gut microbiota in infants at increased risk of dysbiosis — preterm infants, cesarean-born infants, and those receiving antibiotic therapy.
https://www.sciencedirect.com/science/article/pii/S2667009724000071
Chichlowski M, Shah N, Wampler JL, Wu SS, Stephan Mitmesser S. Bifidobacterium longum Subspecies infantis (B. infantis) in Pediatric Nutrition: Current State of Knowledge. Nutrients. 2020;12(6):1581. A review confirming that B. infantis is one of the dominant bacteria in the healthy gut microbiota of infants and that its use in combination with other Lactobacillus and Bifidobacterium strains contributes to the normalization of gut microbiota in early life.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7352178/
Multicomponent formulation – 6 beneficial strains of lactobacilli and bifidobacteria – a targeted combination for gut microbiota development
Babytol Neonate contains a combination of six probiotic strains from the genera Lactobacillus and Bifidobacterium, which represent dominant and functionally important microorganisms in the gut microbiota of infants.
The formulation includes the following strains:
Lactobacillus rhamnosus GG,
Lactobacillus acidophilus,
Lactobacillus reuteri,
Bifidobacterium infantis,
Bifidobacterium bifidum,
Bifidobacterium breve.
These probiotic strains participate in the process of initial gut colonization, contribute to maintaining microbial balance, and play an important role in the development of stable gut microbiota in early life. Bifidobacteria are particularly highlighted, as they constitute a dominant part of the infant microbiota and are associated with healthy digestive system development (Saturio et al., 2021).
A combination of multiple carefully selected probiotic strains may provide broader and complementary support to the sensitive digestive system of newborns, and in preterm infants, combinations of strains from the genera Lactobacillus and Bifidobacterium have shown advantages over single-strain approaches (Morgan et al., 2020).
Source
Saturio S, Nogacka AM, Alvarado-Jasso GM, Salazar N, de Los Reyes-Gavilán CG, Gueimonde M, Arboleya S. Role of Bifidobacteria on Infant Health. Microorganisms. 2021;9(12):2415. MDPI A review documenting the key role of bifidobacteria in the development of infant gut microbiota and their importance for health in early life.
https://pubmed.ncbi.nlm.nih.gov/34946017/
Morgan RL, Preidis GA, Kashyap PC, Weizman AV, Sadeghirad B; McMaster Probiotic, Prebiotic, and Synbiotic Work Group. Probiotics Reduce Mortality and Morbidity in Preterm, Low-Birth-Weight Infants: A Systematic Review and Network Meta-analysis of Randomized Trials. Gastroenterology. 2020;159(2):467–480. A systematic review and network meta-analysis confirming that probiotics reduce mortality and morbidity in preterm, low-birth-weight infants.
https://pubmed.ncbi.nlm.nih.gov/32592699/
After cesarean section – continuous probiotic support in the first months of life
The recommended use is 2 times daily, 7–8 drops, during the first three months of life. This regimen ensures a continuous presence of beneficial bacteria in the digestive tract during the period when gut microbiota is intensively developing and stabilizing.
In babies born by cesarean section, initial gut colonization is delayed due to the lack of exposure to the mother’s microbiome during delivery, which makes the early postnatal period crucial for establishing balanced gut microbiota (Shaterian et al., Open Medicine, 2021).
Regular twice-daily administration provides stable probiotic support during this sensitive period, while the three-month timeframe corresponds to the phase in which gradual formation and normalization of microbiota occurs.
The full effect is achieved by continuing use until the introduction of predominantly non-milk nutrition, when a more diverse diet naturally contributes to further development and diversification of gut microbiota. Clinical studies confirm that continuous probiotic use during this period may contribute to establishing a more stable and functionally balanced microbiota (Korpela et al., Microbiome, 2018).
Source
Shaterian N, Abdi F, Ghavidel N, Abdi F. Role of cesarean section in the development of neonatal gut microbiota: A systematic review. Open Medicine. 2021;16(1):624–639. A systematic review confirming that babies born by cesarean section have significantly slower colonization with beneficial bacteria and that the period of several months after birth is crucial for normalization of gut microbiota.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8035494/
Korpela K, Salonen A, Vepsäläinen O, et al. Probiotic supplementation restores normal microbiota composition and function in antibiotic-treated and in caesarean-born infants. Microbiome. 2018;6(1):182. A randomized, double-blind, placebo-controlled study confirming that probiotic supplementation contributes to normalization of gut microbiota in babies born by cesarean section, with full effect achieved through continuous use until a diverse diet is established.
https://pubmed.ncbi.nlm.nih.gov/30326954/
After antibiotic use – restoration and stabilization of gut microbiota
The recommended use is 2 times daily, 7–8 drops during antibiotic therapy, as well as for at least three weeks after its completion. Administration should be separated from antibiotic use by 2 hours.
Antibiotics, although necessary for the treatment of infections, act non-specifically and reduce both pathogenic and beneficial bacteria in the gut, which may disrupt microbiota balance (Pärnänen et al., Journal of Antimicrobial Chemotherapy, 2018).
For this reason, it is important to start probiotic support already during the course of therapy, in order to mitigate disruption of gut microbiota and preserve its function as much as possible.
After discontinuation of antibiotics, gut microbiota does not immediately return to balance, but requires a period of several weeks for gradual recovery. Continuous probiotic use during this period may contribute to faster normalization of the composition and function of gut microbiota (Korpela et al., Microbiome, 2018).
Source
Pärnänen KMM, Hultman J, Markkanen M, et al. Antibiotic therapy in neonates and impact on gut microbiota and antibiotic resistance development: a systematic review. Journal of Antimicrobial Chemotherapy. 2018;73(3):569–581. A systematic review documenting that antibiotic therapy in the neonatal period leads to a significant reduction in beneficial bacteria and that recovery of gut microbiota after treatment takes several weeks.
https://academic.oup.com/jac/article/73/3/569/4652876
Korpela K, Salonen A, Vepsäläinen O, et al. Probiotic supplementation restores normal microbiota composition and function in antibiotic-treated and in caesarean-born infants. Microbiome. 2018;6(1):182. A randomized study confirming that probiotic supplementation during and after antibiotic therapy contributes to normalization of gut microbiota in newborns.
https://pubmed.ncbi.nlm.nih.gov/30326954/
Preterm infants – dose adjusted according to gestational age
The recommended use depends on the infant’s gestational age and involves dosing 1–2 times daily, 7–8 drops, according to the advice of a pediatrician/neonatologist.
This regimen allows for gradual adaptation of the digestive system to probiotic supplementation. In preterm infants, the digestive tract and gut microbiota are functionally more immature, which is why treatment begins with a lower dose, while infants born closer to term may receive the full daily dose.
The gut microbiota of preterm infants is characteristically depleted of beneficial bacteria, particularly genera such as Lactobacillus and Bifidobacterium, and its stabilization requires a longer period of time (Henderickx et al., Frontiers in Cellular and Infection Microbiology, 2019).
The recommended duration of use of three months is aligned with the phase of intensive development and gradual establishment of microbiota, during which continuous probiotic support may contribute to its normalization (Korpela et al., Microbiome, 2018).
Source
Henderickx JGE, Zwittink RD, van Lingen RA, Knol J, Belzer C. The preterm gut microbiota: an inconspicuous challenge in nutritional neonatal care. Frontiers in Cellular and Infection Microbiology. 2019;9:85. A review documenting that the gut microbiota of preterm infants shows reduced presence of beneficial bacteria and that a period of several months is crucial for normalization with appropriate probiotic support.
https://pubmed.ncbi.nlm.nih.gov/31001489/
Korpela K, Salonen A, Vepsäläinen O, et al. Probiotic supplementation restores normal microbiota composition and function in antibiotic-treated and in caesarean-born infants. Microbiome. 2018;6(1):182. A randomized study confirming the effectiveness of probiotic supplementation in normalizing gut microbiota in newborns at increased risk of dysbiosis.
https://pubmed.ncbi.nlm.nih.gov/30326954/
My baby, given that he was born by caesarean section, received the permitted doses of Babytol Neonate from the first day, and Babytol Coli since we came home. We had no problems with cramps. Actually, maybe there were, but they were very mild, the stool was neat. The baby just breastfeeds and today, after almost 4 months, we don't have any problems and we still use Coli. I think that a month or so is enough and that would be it. I am more than satisfied with the preparations!
Babies born by cesarean section have a specific pattern of gut microbiota development that differs from that of babies born vaginally, primarily due to the lack of exposure to the mother’s microbiome during delivery.
Systematic reviews of recent clinical studies indicate that the use of probiotics may have a positive effect on the composition of gut microbiota in these infants. It has been observed that probiotic supplementation contributes to an increased presence of beneficial bacteria and the gradual establishment of microbiota that becomes more similar in composition and function to that of vaginally born infants (Martín-Peláez et al., Nutrients, 2022).
These findings suggest that targeted probiotic support in the early postnatal period may play a significant role in the normalization of gut microbiota in babies born by cesarean section.
Source
Martín-Peláez S, Cano-Ibáñez N, Pinto-Gallardo M, Amezcua-Prieto C. The Impact of Probiotics, Prebiotics, and Synbiotics during Pregnancy or Lactation on the Intestinal Microbiota of Children Born by Cesarean Section: A Systematic Review. Nutrients. 2022;14(2):341. A systematic review confirming that probiotic use has positive effects on the microbiota of babies born by cesarean section, with colonization becoming similar to that of vaginally born infants.
https://doi.org/10.3390/nu14020341
The mode of delivery may have a long-term impact on the development of a child’s immune system, partly due to differences in the initial colonization of gut microbiota.
Meta-analyses of epidemiological studies indicate that children born by cesarean section have an increased risk of developing certain allergic diseases later in childhood. A higher incidence of allergic rhinitis and asthma has been observed, as well as an increased risk of hospitalization due to asthma attacks and the occurrence of food allergies compared to children born vaginally (Bager et al., Clinical and Experimental Allergy, 2008).
These findings are associated with differences in the development of early immune responses and the composition of gut microbiota, which play an important role in immune system maturation.
For this reason, early use of carefully selected probiotics is increasingly considered as a way to support a more natural development of gut microbiota in children born by cesarean section. Although this cannot be considered a guaranteed prevention of allergic diseases, such an approach may contribute to better development of gut and immune balance and potentially reduce the risk of certain atopic manifestations later in life.
Source
Bager P, Wohlfahrt J, Westergaard T. Caesarean delivery and risk of atopy and allergic disease: meta-analyses. Clinical and Experimental Allergy. 2008;38(4):634–642. A meta-analysis documenting that children born by cesarean section have an increased risk of allergic rhinitis, asthma, hospitalization due to asthma attacks, and food allergies later in life.
https://pubmed.ncbi.nlm.nih.gov/18266879/
Wang F, Fu L, Wang Y, Li W, Wang W. The effect of probiotics in the prevention of atopic dermatitis in children: a systematic review and meta-analysis. Transl Pediatr. 2023;12(5):844-856. doi:10.21037/tp-23-200
The use of antibiotics in the first year of life is very common and represents an important factor that may influence the development of gut microbiota in infants.
Population studies show that approximately 50% of children receive antibiotic therapy at least once by the end of the first year of life (Anderson et al., Journal of Paediatrics and Child Health, 2017).
Given that antibiotics can disrupt the balance of gut microbiota, this high frequency of use further highlights the importance of preserving and restoring microbiota in early life.
Source
Anderson H, Vuillermin P, Jachno K, et al. Prevalence and determinants of antibiotic exposure in infants: A population-derived Australian birth cohort study. Journal of Paediatrics and Child Health. 2017;53(10):942–949. A population study showing that around 50% of children receive antibiotic therapy at least once by the end of the first year of life.
https://pubmed.ncbi.nlm.nih.gov/28749577/
Early use of antibiotics, especially in preterm infants, can have a long-lasting impact on the development of gut microbiota during its most sensitive stage of formation.
Review studies show that antibiotic therapy at this age leads to a reduction in overall microbiome diversity, which is one of the key indicators of a healthy and stable gut microbiota. At the same time, there is a decrease in beneficial bacteria such as Bifidobacterium and Lactobacillus, along with an increase in potentially pathogenic bacteria from the Enterobacteriaceae family (Aires, Frontiers in Microbiology, 2021).
These changes may have prolonged effects on the balance and functional development of gut microbiota, further emphasizing the importance of preserving and supporting gut flora in preterm infants.
Source
Microbiology. 2021;12:681427. A review documenting that early empirical antibiotic therapy has prolonged effects on the gut microbiota of preterm infants — reducing microbiome diversity in favor of harmful bacteria, decreasing bifidobacteria and lactobacilli, and increasing the presence of Enterobacteriaceae.
https://doi.org/10.3389/fmicb.2021.681427
The World Gastroenterology Organisation (WGO), in its guidelines, states that certain probiotic strains have proven use in the treatment of diarrhea in children, particularly in cases associated with infections or antibiotic use.
Among the most commonly recommended strains are Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus reuteri, and Bifidobacterium bifidum, which are associated with shortening the duration of diarrhea and supporting the restoration of gut microbiota (World Gastroenterology Organisation, 2017).
These strains are part of probiotic formulations used in pediatric practice due to their safety and documented effects in supporting digestive health in children.
Source
World Gastroenterology Organisation. Probiotics and Prebiotics. WGO Global Guidelines. 2017. Guidelines recommending the use of L. rhamnosus GG, L. acidophilus, L. reuteri, and B. bifidum for the treatment of diarrhea in children.
https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2017.pdf
The use of antibiotics in children can disrupt gut microbiota, increasing the risk of antibiotic-associated diarrhea.
A review of clinical studies shows that probiotics may have a protective effect in this context. An analysis of 22 clinical studies indicates that probiotic use contributes to reducing the incidence of antibiotic-associated diarrhea in children, as well as maintaining the balance of gut microbiota during therapy (Hayes and Vargas, Explore, 2016).
These findings support the use of probiotics as an additional nutritional support during antibiotic therapy, particularly in the pediatric population.
Source
Hayes SR, Vargas AJ. Probiotics for the Prevention of Pediatric Antibiotic-Associated Diarrhea. Explore. 2016;12(6):463–466. A review of 22 clinical studies confirming that probiotics have a protective effect in preventing antibiotic-associated diarrhea in children.
https://pubmed.ncbi.nlm.nih.gov/27688016/
Preterm newborns belong to a high-risk group for serious gastrointestinal and systemic complications, including necrotizing enterocolitis (NEC), which is one of the most severe conditions in the neonatal period.
Cochrane systematic reviews, which combine results from a large number of randomized clinical trials, indicate that the use of probiotics in preterm newborns may be associated with a reduced risk of necrotizing enterocolitis, as well as lower mortality rates in this population (Sharif et al., Cochrane Database of Systematic Reviews, 2020).
These findings further confirm the importance of gut microbiota in early development and suggest a potential role of probiotic support in this particularly vulnerable population of preterm infants.
Source
Sharif S, Meader N, Oddie SJ, Rojas-Reyes MX, McGuire W. Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants. Cochrane Database of Systematic Reviews. 2020;10:CD005496. A Cochrane systematic review confirming that probiotic use in preterm newborns reduces the risk of mortality and necrotizing enterocolitis.
https://pubmed.ncbi.nlm.nih.gov/33058137/
Necrotizing enterocolitis (NEC) is one of the most serious gastrointestinal complications in preterm newborns and is associated with the immaturity of the intestinal barrier and microbiota imbalance.
Systematic reviews and meta-analyses of clinical studies indicate that the use of probiotics may contribute to reducing the risk of NEC in preterm infants. Results show that probiotic supplementation has a protective effect on the intestinal mucosa and contributes to the stabilization of microbiota during this sensitive period (Aceti et al., Italian Journal of Pediatrics, 2015).
These findings further confirm the importance of early support of gut microbiota in preterm infants, particularly in the context of preventing serious gastrointestinal complications.
Source
Aceti A, Gori D, Barone G, et al. Probiotics for prevention of necrotizing enterocolitis in preterm infants: systematic review and meta-analysis. Italian Journal of Pediatrics. 2015;41:89. A systematic review and meta-analysis confirming that probiotic use reduces the risk of necrotizing enterocolitis in preterm infants.
https://doi.org/10.1186/s13052-015-0199-2
Preterm newborns have an increased risk of hospital-acquired infections, including neonatal sepsis, due to the immaturity of the immune system and impaired intestinal barrier function.
Review studies indicate that probiotic use may be associated with a reduced incidence of hospital-acquired sepsis in this population, as well as beneficial effects on other important clinical outcomes such as necrotizing enterocolitis (NEC) and overall mortality (Underwood, Current Opinion in Pediatrics, 2019).
These effects are linked to the role of probiotics in stabilizing gut microbiota and strengthening intestinal barrier integrity, which may help reduce the translocation of pathogenic bacteria.
Available data also indicate that probiotic use in this population is generally well tolerated, with a favorable safety profile under controlled conditions.
Source
Underwood MA. Arguments for routine administration of probiotics for NEC prevention. Current Opinion in Pediatrics. 2019;31(2):188–194. A review confirming that probiotic use reduces the risk of mortality, necrotizing enterocolitis, and hospital-acquired sepsis in preterm infants and is generally safe.
https://pubmed.ncbi.nlm.nih.gov/30664022/
Recommendations for the use of probiotics in pediatrics include various situations in which gut microbiota is disrupted or develops under specific conditions.
According to national guidelines of the Serbian Pediatric Association, the use of probiotics is recommended in newborns and infants in several clinical situations, including babies born by cesarean section, children who are undergoing or have recently completed antibiotic therapy, as well as preterm infants (Serbian Pediatric Association – Position on the use of probiotics in newborns – 2023).
These recommendations are based on the need to support the establishment and maintenance of balanced gut microbiota during periods when its development is particularly sensitive or disrupted by external factors.
Source
Serbian Pediatric Association – Position on the use of probiotics in newborns (Positions on the use of probiotics in neonatology are further detailed in the brochure “Probiotics in Neonatology,” by B. Janković, J. Martić, T. Nikolić)
https://www.udruzenjepedijatara.rs/wp-content/uploads/2023/08/AZURIRAN_STAV_O_PRIMENI_PROBIOTIKA_KOD_NOVORO.pdf
Please note that the referenced clinical studies and scientific sources relate to individual product ingredients and their effects, not to the product as a whole.
Babytol Neonate and Babytol COLI can be administered at the same time. The doses are adjusted so that there is no danger if used together,
Babytol Neonate for you! contains a combination of six useful strains of lactobacilli and bifidobacteria that significantly increase the effectiveness of this preparation. These are: Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus reuteri, Bifidobacterium infantis, Bifidobacterium bifidum, Bifidobacterium breve.
Babytol Neonate is intended to normalize intestinal flora in premature babies and babies born by caesarean section, as well as in newborns and young children who are on antibiotic therapy.
Babytol Neonate is also recommended for use in young children who are on antibiotic therapy.
Babytol Neonate are oral drops, which are added to breast milk or milk formulas.
Copyright 2026 4uPharma. All Rights Reserved
Dajbog CMS, izrada sajta i SEO by Web Business Solutions
